Oltipraz is an antischistosomiasis drug found to inhibit carcinogenesis. It is effective against several chemically induced tumor models. Its mechanism of action is believed to be the induction of phase II detoxifying enzymes resulting in diminished carcinogen-DNA binding. Oltipraz is an activator of Nrf2.
Bueding E, Dolan P, Leroy JP. Res Commun Chem Pathol Pharmacol. 37:293-303 (1982). Wattenberg LW, Bueding E. Carcinogenesis. 7:1379-81 (1986). Kensler T, Styczynski P, Groopman J et al. J Cell Biochem Suppl. 16I:167-72 (1992).
Soluble in methanol, and DMSO ( >20 mg/ml).
Store at 4° C
n20D 1.76 (Predicted)
CYP1A2: Ki= 9 µM (human)
pKb: 0.18 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Download SDS (MSDS)
Certificate of Analysis
Adobe Acrobat Reader is required to reliably view, print and comment on PDF documents
bvseo_sdk, java_sdk, bvseo-3.2.0
CLOUD, getContent, 65ms
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
EbaEba, S. et al. (PubMed 23590302) reported that the nuclear factor erythroid 2-related factor 2 activator Oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn
Create a new account
Email address already exists, please enter a new valid email address.Hide
USE YOUR SOCIAL NETWORK
Create an account quickly and easily with your preferred social network account. You won't have to remember an extra name and password.
Creating an account with us makes your shopping experience much easier and faster. You can save favorites, save cart, check order status and speed through checkout with saved addresses, payment methods and more.